SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
FDA
Gilead’s Next-Gen HIV Drug Heads to the FDA, Stock Soars
April 8, 2015
 · 
2 min read
Biowarfare Company Emergent's Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle
Business
Is Gilead CEO Worth The Money?
April 7, 2015
 · 
6 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
Gilead and Amgen Hand Out Dividends; Other Biotechs Feel the Heat So Who’s Next?
April 6, 2015
 · 
4 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Biotech Bay
Should Gilead Feel Threatened by Achillion’s Next-Generation Hep C Drug?
April 2, 2015
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest
March 23, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead’s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV
February 27, 2015
 · 
6 min read
Biotech Bay
Gilead Holds Cash Overseas to Save Billions on Taxes
February 27, 2015
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Biotech Bay
Critics Attack as Gilead Has a Pill to Stop HIV, But Why Isn’t Anyone Taking It?
February 19, 2015
 · 
2 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Biotech Bay
ViiV Healthcare Wins for Corporate Reputation With Patients While Gilead Freefalls Down List
February 16, 2015
 · 
2 min read
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Gilead Sciences, Inc. Will Charge $900 For Sovaldi In India
August 8, 2014
 · 
1 min read
Biotech Bay
Gilead Sciences, Inc. Battles To Shift Debate Over $1,000 Hepatitis Pills From Costs To Cures
August 5, 2014
 · 
1 min read
Business
Theraclone Sciences, Inc. Announces Exclusive Agreement With Gilead Sciences, Inc. For Broadly Neutralizing HIV Antibodies
July 30, 2014
 · 
2 min read
Gilead Sciences, Inc. Allows China/Indian Pharmas To Make Generic Version Of Novel HIV Drug
July 30, 2014
 · 
1 min read
Biotech Bay
European CHMP Adopts Positive Opinion For Gilead Sciences, Inc.’s Zydelig® (Idelalisib) For The Treatment Of Chronic Lymphocytic Leukemia And Follicular Lymphoma
July 25, 2014
 · 
1 min read
Business
Gilead Sciences, Inc. Announces Second Quarter 2014 Financial Results
July 24, 2014
 · 
1 min read
Business
Hepatitis B Drug Rockets Gilead Sciences, Inc. Into The Big Leagues
July 24, 2014
 · 
1 min read
Business
Gilead Sciences, Inc., Medicines Patent Pool Strike Deal: New Opportunity For Indian Drugmakers
July 24, 2014
 · 
4 min read
FDA
FDA Approves Gilead Sciences, Inc.'s Zydelig® (idelalisib) For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma
July 23, 2014
 · 
13 min read
Biotech Bay
New Analysis Suggests Pricey Gilead Sciences, Inc. Drug Will Bust State Budgets
July 18, 2014
 · 
1 min read
Load More